ReviewThe review of diabetic studies : RDS2011
Islet transplantation and encapsulation: an update on recent developments.
Review in The review of diabetic studies : RDS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Article
- Article
- Intrasplenic Transplantation of Islets With a Platelet Shielding System Restores Glycemic Control.Diabetes · 2025Article
- Immunomodulatory agents and cell therapy for patients with type 1 diabetes.Archives of endocrinology and metabolism · 2025Review
- Navigating challenges in human pluripotent stem cell-derived islet therapy for type 1 diabetes.Frontiers in immunology · 2025Review
- Immunoprotection Strategies in β-Cell Replacement Therapy: A Closer Look at Porcine Islet Xenotransplantation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- 3D printed elastomeric biomaterial mitigates compaction during in vitro vasculogenesis.Acta biomaterialia · 2023Article
- Combinatorial islet protective therapeutic approaches in β-cell transplantation: Rationally designed solutions using a target product profile.FASEB bioAdvances · 2023Review
- Engineering Modular, Oxygen-Generating Microbeads for the In Situ Mitigation of Cellular Hypoxia.Advanced healthcare materials · 2023Article
- A predictive computational platform for optimizing the design of bioartificial pancreas devices.Nature communications · 2022Article
- Microencapsulation-based cell therapies.Cellular and molecular life sciences : CMLS · 2022Review
- Highly Efficient Differentiation of Human Pluripotent Stem Cells into Pancreatic Progenitors Co-expressing PDX1 and NKX6.1.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Artificial Cell Encapsulation for Biomaterials and Tissue Bio-Nanoengineering: History, Achievements, Limitations, and Future Work for Potential Clinical Applications and Transplantation.Journal of functional biomaterials · 2021Review
- Injectable biomaterial shuttles for cell therapy in stroke.Brain research bulletin · 2021Review
- A therapeutic vascular conduit to support in vivo cell-secreted therapy.NPJ Regenerative medicine · 2021Article
- Immunological considerations and challenges for regenerative cellular therapies.Communications biology · 2021Review
- Exosome loaded immunomodulatory biomaterials alleviate local immune response in immunocompetent diabetic mice post islet xenotransplantation.Communications biology · 2021Article
- C-Peptide as a Therapy for Type 1 Diabetes Mellitus.Biomedicines · 2021Review
- Effect of alginate matrix engineered to mimic the pancreatic microenvironment on encapsulated islet function.Biotechnology and bioengineering · 2021Article
- Facilitating islet transplantation using a three-step approach with mesenchymal stem cells, encapsulation, and pulsed focused ultrasound.Stem cell research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human islet transplantation can provide good glycemic control in diabetic recipients without exogenous insulin. However, a major factor limiting its application is the recipient's need to adhere to life-long immunosuppression, something that has serious side effects. Microencapsulating human islets is a strategy that should prevent rejection of the grafted tissue without the need for anti-rejection drugs. Despite promising studies in various animal models, the encapsulated human islets so far have not made an impact in the clinical setting. Many non-immunological and immunological factors such as biocompatibility, reduced immunoprotection, hypoxia, pericapsular fibrotic overgrowth, effects of the encapsulation process and post-transplant inflammation hamper the successful application of this promising technology. In this review, strategies are discussed to overcome the above-mentioned factors and to enhance the survival and function of encapsulated insulin-producing cells, whether in islets or surrogate β-cells. Studies at our center show that barium alginate microcapsules are biocompatible in rodents, but not in humans, raising concerns over the use of rodents to predict outcomes. Studies at our center also show that the encapsulation process had little or no effect on the cellular transcriptome of human islets and on their ability to function either in vitro or in vivo. New approaches incorporating further modifications to the microcapsule surface to prevent fibrotic overgrowth are vital, if encapsulated human islets or β-cell surrogates are to become a viable therapy option for type 1 diabetes in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.